Zurich, Switzerland – Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It is caused by mutations in a large number of genes that are acquired in the course of a person’s life. One of these genes – the tumor suppressor gene TP53 – plays a key role....
Latest News
Chengdu, China – Dementia stands as one of the most significant global health challenges of the 21st century, with over 50 million individuals worldwide currently affected, a number projected to triple by 2050, reaching 152 million, due to global population aging. Alzheimer’s disease (AD) is the predominant cause of dementia,...
Jerusalem, Israel – Professor Asaf Hellman and his research team at the Hebrew University-Hadassah Medical School have unveiled new findings in the realm of methylation-directed regulatory networks. Their study sheds light on the mechanisms governing the activation and suppression of mutation-driven disease genes, particularly in cases like glioblastoma, offering insights...
Tokyo, Japan – Autism spectrum disorder (ASD) is a complex neuropsychiatric condition, marked by diverse cognitive and sensorimotor challenges, difficulties with social communication, and distinct behavioral patterns. While genetic factors are known to play a role, the intricate mechanisms driving this condition remain elusive. Moreover, a unified and comprehensive theoretical...
DURHAM, N.C. – Autoimmune diseases are mysterious. It wasn’t until the 1950s that scientists realized that the immune system could harm the organs of its own body. Even today, the fundamental causes and inner workings of most autoimmune diseases remain poorly understood, limiting the treatment options for many of these...
PITTSBURGH, Pennsylvania, and JERUSALEM, Israel — The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell – Teva Joint Venture announced today that the Institute has joined an elite group of cancer centers in Europe, the United States and Israel that are now enrolling patients to participate in the...
AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of...
Treatment-free remission (TFR) is feasible after 2 or more years of frontline nilotinib treatment in patients with chronic myeloid leukemia in chronic phase (CML-CP), reported researchers in a study published in Leukemia. Advances in the treatment of CML have improved outcomes for those with the disease; however, long-term treatment with tyrosine...
Treatment-free remission (TFR) is feasible after 2 or more years of frontline nilotinib treatment in patients with chronic myeloid leukemia in chronic phase (CML-CP), reported researchers in a study published in Leukemia. Advances in the treatment of CML have improved outcomes for those with the disease; however, long-term treatment with tyrosine...
Memphis, Tenn – Compared to adult cancers, pediatric cancers often have distinctive genetic causes. This means there is an opportunity to develop pediatric-focused diagnostic strategies and treatments. Research by St. Jude Children’s Research Hospital published today in Nature Genetics clarifies the genomic landscape of pediatric acute myeloid leukemia (pAML). The...